Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Mitsubishi Tanabe Pharma Announces Approval of RADICAVA® Oral Suspension in Switzerland

Wednesday, May 10, 2023

Mitsubishi Tanabe Pharma Corporation announced that its wholly owned subsidiary, Mitsubishi Tanabe Pharma obtained the approval from Authority of Switzerland (Swissmedic) to RADICAVA® Oral Suspension for the indication of amyotrophic lateral sclerosis. RADICAVA® Oral Suspension will be commercialised by MTPD in Switzerland.

RADICAVA® Oral Suspension offers the same efficacy as edaravone for intravenous infusion, a treatment shown in a pivotal trial to help slow the loss of physical function in ALS. RADICAVA® Oral Suspension formulation serves as a new treatment option for ALS patients in order to address unmet needs of people living with ALS.

RADICAVA® Oral Suspension is specifically formulated for patients with ALS and provides a flexible administration option with a 5ml dose taken orally or via feeding tube. One cycle of administration of RADICAVA® Oral Suspension is a total of 28 days, including both the dosing period and the drug-free period, and that cycle is repeated. 

RADICAVA® Oral Suspension are available in bottles and do not require water or solution to administer. RADICAVA® Oral Suspension needs to be refrigerated during the distribution process and in pharmacies, but patients can keep it at room temperature.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024